文献速递肿瘤 PET/CT

使用[18F]AlF-NOTA-PRGD2 PET显像对葡萄膜黑色素瘤的超灵敏检测

Ultrasensitive detection of uveal melanoma using [18F]AlF-NOTA-PRGD2 PET imaging.
PubMed 文献 · EJNMMI Res · 2024-07-05

本研究在92-1葡萄膜黑色素瘤细胞系、皮下及眼部原发葡萄膜黑色素瘤异种移植模型和葡萄膜黑色素瘤患者中评估[18F]AlF-NOTA-PRGD2 PET显像的诊断效果,并与[18F]FDG PET进行比较。结果显示[18F]AlF-NOTA-PRGD2在异种移植模型和患者中均能清晰显示肿瘤,且敏感性和特异性高于[18F]FDG。作者认为[18F]AlF-NOTA-PRGD2 PET显像可能较[18F]FDG PET更适于原发葡萄膜黑色素瘤诊断,并似乎也适用于肝转移患者的诊断。

要点

  • 在92-1葡萄膜黑色素瘤细胞系中,[18F]AlF-NOTA-PRGD2具有高细胞摄取、细胞结合能力和体外稳定性。
  • 注射后60分钟,皮下和眼部原发葡萄膜黑色素瘤异种移植模型均清晰显影,建模后7天两部位肿瘤摄取分别为2.55±0.44%ID/g和1.73±0.15%ID/g。
  • 与[18F]FDG相比,[18F]AlF-NOTA-PRGD2在异种移植模型和患者中对葡萄膜黑色素瘤PET显像显示更高的敏感性和特异性。

核心结论

  • 作者认为,与[18F]FDG PET显像相比,[18F]AlF-NOTA-PRGD2 PET显像可能是诊断原发葡萄膜黑色素瘤更优先的方法。
  • 由于肿瘤与本底比值高,[18F]AlF-NOTA-PRGD2 PET显像似乎也适用于葡萄膜黑色素瘤肝转移患者的诊断。

研究设计与样本

  • 在92-1葡萄膜黑色素瘤细胞系中评估[18F]AlF-NOTA-PRGD2的细胞摄取、细胞结合能力和体外稳定性。
  • 在92-1葡萄膜黑色素瘤异种移植模型中进行MicroPET显像和生物分布研究。
  • 招募葡萄膜黑色素瘤患者评估[18F]AlF-NOTA-PRGD2 PET显像的诊断效果(ClinicalTrials.gov注册号NCT02441972)。
  • 在葡萄膜黑色素瘤异种移植模型和患者中比较[18F]AlF-NOTA-PRGD2与[18F]FDG PET显像。

主要发现

  • 体外数据显示[18F]AlF-NOTA-PRGD2在92-1葡萄膜黑色素瘤细胞系中具有高细胞摄取、细胞结合能力和体外稳定性。
  • 体内数据显示注射后60分钟,皮下和眼部原发葡萄膜黑色素瘤异种移植模型均可用[18F]AlF-NOTA-PRGD2清晰显影。
  • 动物模型构建后7天,皮下和眼部原发肿瘤的示踪剂摄取分别为2.55±0.44%ID/g和1.73±0.15%ID/g。
  • 临床数据显示注射后60分钟葡萄膜黑色素瘤患者肿瘤可用[18F]AlF-NOTA-PRGD2清晰显影。
  • 与[18F]FDG相比,[18F]AlF-NOTA-PRGD2在异种移植模型和患者中对葡萄膜黑色素瘤PET显像显示更高的敏感性和特异性。

临床怎么用

  • 作者认为[18F]AlF-NOTA-PRGD2 PET显像可能是诊断原发葡萄膜黑色素瘤更优先的方法。
  • 作者认为由于肿瘤与本底比值高,[18F]AlF-NOTA-PRGD2 PET显像似乎也适用于葡萄膜黑色素瘤肝转移患者的诊断。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Uveal melanoma (UM) is the most common primary intraocular tumor in adults, and early detection is critical to improve the clinical outcome of this disease. In this study, the diagnostic effectiveness of [18F]AlF-NOTA-PRGD2 (an investigational medicinal product) positron emission tomography (PET) imaging in UM xenografts and UM patients were evaluated. The cell uptake, cell binding ability and in vitro stability of [18F]AlF-NOTA-PRGD2 were evaluated in 92-1 UM cell line. MicroPET imaging and biodistribution study of [18F]AlF-NOTA-PRGD2 were conducted in 92-1 UM xenografts. Then, UM patients were further recruited for evaluating the diagnostic effectiveness of [18F]AlF-NOTA-PRGD2 PET imaging (approval no. NCT02441972 in clinicaltrials.gov). In addition, comparison of [18F]AlF-NOTA-PRGD2 and 18F-labelled fluorodeoxyglucose ([18F]FDG) PET imaging in UM xenografts and UM patients were conducted. RESULTS: The in vitro data showed that [18F]AlF-NOTA-PRGD2 had a high cell uptake, cell binding ability and in vitro stability in 92-1 UM cell line. The in vivo data indicated that 92-1 UM tumors were clearly visualized with the [18F]AlF-NOTA-PRGD2 tracer in the subcutaneous and ocular primary UM xenografts model at 60 min post-injection. And the tumor uptake of the tracer was 2.55 ± 0.44%ID/g and 1.73 ± 0.15%ID/g at these two tissue locations respectively, at 7 days after animal model construction. The clinical data showed that tumors in UM patients were clearly visualized with the [18F]AlF-NOTA-PRGD2 tracer at 60 min post-injection. In addition, [18F]AlF-NOTA-PRGD2 tracer showed higher sensitivity and specificity for PET imaging in UM xenografts and UM patients compared to [18F]FDG tracer. CONCLUSION: [18F]AlF-NOTA-PRGD2 PET imaging may be a more preferred approach in the diagnosis of primary UM compared to [18F]FDG PET imaging. Additionally, due to the high tumor-to-background ratio, [18F]AlF-NOTA-PRGD2 PET imaging seems also to be applicable for the diagnosis of UM patients with liver metastasis. TRIAL REGISTRATION: ClinicalTrials.gov: NCT02441972, Registered 1 January 2012, https://clinicaltrials.gov/study/NCT02441972 .

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Wang L, Zhu X, Xue Y, et al. Ultrasensitive detection of uveal melanoma using [18F]AlF-NOTA-PRGD2 PET imaging. EJNMMI Res. 2024. PMID: 38967722. doi:10.1186/s13550-024-01123-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。